Transgene and NEC Report TG4050 Phase 1 Success

Transgene and NEC Corporation have announced a sustained 100% three-year disease-free survival (DFS) rate for patients treated with TG4050 in the Phase 1 portion of a randomized Phase 1/2 clinical trial. Evaluated as an adjuvant treatment for patients with resected, locally advanced HPV-negative head and neck squamous cell carcinoma (HNSCC), all 16 patients who received the vaccine remained disease-free after a median follow-up of 41 months. In contrast, three of the 16 patients in the control arm experienced a relapse during the same period. The comprehensive clinical and translational findings have also been officially published in the peer-reviewed journal Nature Communications.

The published data highlights robust and persistent neoantigen-specific CD8+ T-cell responses in 73.3% of the treated patients. Notably, this vaccine-induced immunity was maintained throughout the treatment phase and persisted for more than a year after the final vaccination. TG4050, which encodes up to 30 patient-specific tumor targets prioritized by NEC’s artificial intelligence prediction system, continues to demonstrate a favorable safety profile with no unexpected side effects.

Additional Context
This section provides technological and market background not explicitly detailed in the original release.

Head and neck squamous cell carcinoma (HNSCC) is an aggressive cancer with a notoriously high rate of recurrence, even after patients undergo intensive surgery and chemoradiotherapy. Traditional, off-the-shelf immunotherapies often struggle to generate a durable response in these patients due to the immune-evasive nature of the tumors. TG4050 represents a shift toward highly personalized oncology by combining advanced artificial intelligence with viral vector delivery. NEC’s AI-powered Neoantigen Prediction System sequences a patient's specific tumor tissue to identify the most immunogenic mutated proteins (neoantigens). Transgene's myvac^® platform then engineers a bespoke viral vector to deliver these unique targets back into the patient. This highly targeted approach trains the patient's immune system to hunt down and eliminate microscopic residual disease before a full clinical relapse can occur, marking a major milestone for AI-driven precision medicine.

Edited by Lekshman Ramdas, Induportals editor – adapted by AI.

www.nec.com